Zynerba Pharmaceuticals (ZYNE) Rises High After U.S. Patent Approval

 

Shares of Zynerba Pharmaceuticals (ZYNE) stock are higher today after the company announced it received a U.S. patent titled “Treatment of Fragile X Syndrome with Cannabidiol”. The patent includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol.

Fragile X syndrome is a genetic disorder that causes mild to severe intellectual disabilities. Symptoms may include hyperactive behavior, delayed speech, anxiety and seizures, and are typically more severe in males than females. Fragile X syndrome can also cause physical abnormalities.

What’s Happening with ZYNE Stock Today

ZYNE stock is trading at $5.34 as of 11:27 AM on Tuesday, Feb 26, a rise of $0.30, or 5.95% from the previous closing price of $5.04. ZYNE stock has traded between $5.27 and $5.90 so far today. Volume today is elevated. So far 3,391,201 shares have traded compared to average volume of 1,213,395 shares.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 46 out of a possible 100. That score is based on three component scores. A fundamental score of 75, a long-term technical score of 40 and a short-term technical score of 23. Our proprietary system combines short and long-term technical factors, Wall Street’s opinion, and other fundamental factors into an overall score that measures a stock’s suitability for investment.

The major indices are headed in different directions. The S&P 500 has risen 0.03%. The S&P 500 has risen 0.03%. The Dow Jones Industrial Average is lower by -0.02%.

Get more analysis and trade ideas on Zynerba Pharmaceuticals (ZYNE) stock.

Symbols: ZYNE

You May Also Like